1,802 results on '"Saunders, Mark"'
Search Results
2. JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors
3. University Press Forum 2015: Measuring Success: The Value of Our Work Can’t Always Be Captured in a Spreadsheet
4. Genetic and immune landscape evolution in MMR‐deficient colorectal cancer
5. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation
6. Supplementary Table S2 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
7. Supplementary Methods S1 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
8. Data from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
9. Supplementary Figure S1 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
10. Building and Maintaining Trust in Virtual Teams
11. Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study
12. Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
13. Human resource management in the age of generative artificial intelligence: Perspectives and research directions on ChatGPT
14. SCOT: Tumor Sidedness and the Influence of Adjuvant Chemotherapy Duration on Disease Free Survival (DFS)
15. Overall survival results for trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab: Results from the phase 3 SOLSTICE study.
16. Contextual Framework for Developing Research Competence: Piloting a Validated Classroom Model
17. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation
18. Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasets
19. How to Keep your Doctorate on Track
20. Publications, what publications?
21. Time is waiting in the wings
22. What we wish we had known: lessons learned to keep your doctorate on track
23. RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases
24. PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer
25. The Mental Health Burden of Patients with Colorectal Cancer Receiving Care during the COVID-19 Pandemic: Results of the PICO-SM Study
26. Durvalumab (MEDI 4736) with extended neoadjuvant regimens in rectal cancer: A randomised phase II trial (PRIME-RT).
27. Trifluridine–tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study
28. The case of the suburban expanders
29. In Memoriam: John (Jack) Alexander, DVM
30. Quality-of-life outcomes in older patients with early-stage rectal cancer receiving organ-preserving treatment with hypofractionated short-course radiotherapy followed by transanal endoscopic microsurgery (TREC): non-randomised registry of patients unsuitable for total mesorectal excision
31. Trust, distrust and human resource management
32. 9 The Vow and Tourist Travel
33. Migration and Job Vacancy Information
34. Education for people involved in dairy production : what is required to enhance future productivity?
35. RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases
36. PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer
37. Enhancing data mobilisation through a centralised data repository for Atlantic salmon (Salmo salar L.): Providing the resources to promote an ecosystem-based management framework.
38. How to Keep Your Research Project on Track
39. Choosing Participants
40. Clinical and radiomics prediction of complete response in rectal cancer pre-chemoradiotherapy
41. Special Issue: The Future of Qualitative Methods
42. Arthur Robert “Bob” Twardock (1931–2021)
43. A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments.
44. Modification to Systemic Anticancer Therapy at the Start of the COVID-19 Pandemic and its Overall Impact on Survival Outcomes in Patients with Colorectal Cancer
45. NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumor mutation burden for high-risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer.
46. Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer
47. Starting up, not slowing down: Social entrepreneurial intentions in later working-life
48. SCOT – Short Course Oncology Therapy – A Study of Adjuvant Chemotherapy in Colorectal Cancer v1
49. In Memoriam: Ellis Madison Hall (1930–1921)
50. A Phase II trial of Higher RadiOtherapy Dose In The Eradication of early rectal cancer (APHRODITE): protocol for a multicentre, open-label randomised controlled trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.